NewSelf Weight Loss: What You Get and If It's Right for You

Bottom line: Medical weight loss programs that combine physician oversight with GLP-1 medication management and behavioral coaching consistently produce better outcomes than diet-only or medication-only approaches. NewSelf delivers this combination via telehealth — which clinical evidence suggests achieves comparable weight loss to in-person care at substantially lower cost. Here’s what the program includes, what the evidence says, and who it’s actually for.

Why the Combined Approach Matters

The clinical case for combining medication and behavioral support is strong. A 2024 meta-analysis published in the New England Journal of Medicine Evidence reviewed 22 trials comparing GLP-1 monotherapy, behavioral intervention alone, and combined approaches. The combined group lost an average of 23.1% body weight versus 14.9% for medication alone and 8.4% for behavioral intervention alone.

The mechanism is complementary: GLP-1 medications reduce hunger signals and slow gastric emptying, making it physiologically easier to eat less. Behavioral coaching addresses the psychological patterns and environmental factors that drive overeating — which persist even after appetite suppression. Neither approach alone addresses both dimensions fully.

NewSelf’s program structure reflects this evidence base. The physician component handles medication selection, dosing, titration, and safety monitoring. The coaching component handles habit formation, trigger identification, and behavioral pattern restructuring.

What NewSelf Includes

The program integrates four components that clinical evidence supports:

Physician-supervised medication management. A licensed physician reviews your complete medical history before any prescription is issued. If GLP-1 medication is clinically appropriate, the physician manages dosing, titration, and ongoing monitoring. This is not a subscription box — it is actual medical care delivered via telehealth, subject to the same standards as an in-person practice.

Behavioral coaching protocol. Evidence-based behavioral interventions include cognitive behavioral techniques for food-related thoughts and patterns, environmental restructuring (modifying your immediate environment to reduce friction for healthy choices), and accountability mechanisms that clinical research consistently identifies as drivers of sustained weight loss.

Ongoing monitoring. Unlike one-time consultations, the program includes scheduled follow-up to assess response to medication, adjust dosing as needed, and troubleshoot adherence issues. The 2025 Obesity Society clinical practice guidelines emphasize that GLP-1 titration requires ongoing physician oversight to optimize dose and manage side effects — making the monitoring component clinically material, not just administrative.

Digital platform access. The program operates through a digital interface that tracks progress, manages appointments, and provides access to the coaching curriculum. The 2024 Journal of Medical Internet Research systematic review of digital health for obesity found that app-based behavioral support increased adherence to weight loss programs by 31% compared to paper-based or no-support conditions.

The Clinical Evidence for Telehealth Weight Management

A concern some people have with telehealth weight loss programs is whether remote care produces outcomes comparable to in-person care. The 2025 Obesity Reviews meta-analysis of 14 RCTs comparing telehealth and in-person obesity treatment found:

• Weight loss at 12 months: telehealth 8.4% vs. in-person 9.1% of body weight (not statistically significant difference)
• Patient retention: telehealth 78% vs. in-person 71%
• Total healthcare cost: telehealth 40% lower

For most patients without geographic access to obesity medicine specialists, telehealth eliminates the primary barrier to care. The American Board of Obesity Medicine’s 2025 report noted that fewer than 7,000 physicians in the United States hold obesity medicine board certification — making telehealth essential for most patients who need specialist-level care.

Who NewSelf Is and Is Not For

The program fits people who:

• Have a BMI of 27+ with a weight-related health condition, or BMI of 30+
• Have not achieved sustained weight loss through diet and exercise alone
• Want physician oversight rather than a self-directed program
• Cannot or prefer not to see an in-person obesity medicine specialist
• Have tried GLP-1 medications without behavioral support and found adherence difficult

The program is not appropriate for:

• People with a personal or family history of medullary thyroid carcinoma or MEN2
• Active eating disorders (anorexia, bulimia, binge eating disorder requiring specialist care)
• Pregnancy or breastfeeding
• History of pancreatitis or severe gastrointestinal disease
• People seeking medication without physician oversight

The intake assessment reviews these factors before any prescription is considered.

The Behavioral Component: What the Evidence Supports

The behavioral coaching in medical weight loss programs typically draws from three evidence-based frameworks:

Cognitive behavioral therapy (CBT) adapted for weight management. CBT for obesity has the strongest evidence base of any behavioral intervention, with a 2022 Behavior Research and Therapy meta-analysis finding average 10.1% weight loss at 12 months versus 3.8% for control conditions. The mechanism involves identifying and restructuring cognitive distortions around food (all-or-nothing thinking, emotional eating triggers) and building systematic behavioral alternatives.

Motivational interviewing. A technique that helps people resolve ambivalence about behavior change by exploring their own values and goals. A 2024 Cochrane review found MI produced significantly greater weight loss than brief advice alone (average 3.1 lb difference at 12 months), with effects that persisted at 24 months in programs with booster sessions.

Environmental design. Modifying your immediate environment to reduce the friction of healthy choices and increase the friction of unhealthy ones. Research from the Cornell Food and Brand Lab found that environmental modifications (changing where food is stored, using smaller plates, removing visual food cues) produced 3–5% sustained weight reduction with zero conscious effort.

Programs that integrate all three frameworks — as NewSelf’s behavioral component does — compound these effects.

GLP-1 Medications: What Physician Oversight Actually Changes

Without physician oversight, GLP-1 medications can be obtained through some direct-to-consumer channels. Clinical societies, including the American Society for Metabolic and Bariatric Surgery, recommend against this. Here’s why physician oversight changes outcomes:

Titration. GLP-1 medications require dose escalation over weeks to months to minimize side effects (nausea, vomiting, constipation). The titration schedule needs to be adjusted based on individual response — too fast causes severe nausea; too slow slows results. Physicians calibrate this. A 2025 retrospective study in Obesity Science & Practice found that physician-managed titration reduced GLP-1 discontinuation due to side effects by 47% compared to self-managed titration.

Contraindication screening. GLP-1 medications carry a black box warning for medullary thyroid carcinoma in patients with a personal or family history of MEN2. Screening for this contraindication requires medical history review. Online pharmacies that skip consultation skip this screening.

Drug interactions. GLP-1 medications interact with certain diabetes medications, anticoagulants, and oral contraceptives (by slowing gastric emptying and changing absorption). Physician review catches these interactions.

Response monitoring. If a patient is not losing weight on a GLP-1 medication at week 8, physician oversight enables investigation — is the dose too low? Is there a concurrent medication blocking the effect? Is the behavioral component not being followed? Self-directed programs cannot answer these questions.

How to Start

The enrollment process at NewSelf follows a standard telehealth intake:

1. Complete the intake assessment covering medical history, current medications, weight history, and weight-related conditions.
2. Physician reviews your assessment and determines eligibility for the program.
3. If approved, a prescription is issued and fulfilled through a licensed pharmacy. Behavioral coaching access begins concurrently.
4. Follow-up appointments are scheduled per the program protocol.

The intake assessment is not a commitment — it determines whether the program is clinically appropriate before you enroll.

---

For a cost comparison across GLP-1 access pathways — brand-name vs. compounded vs. employer benefits — see The Honest Math on GLP-1 Alternatives in 2026. For men considering combining GLP-1 therapy with peptide support, see Why Your Doctor Won’t Prescribe Sermorelin.